AJ Bell's Russ Mould, Danni Hewson and Dan Coatsworth point out that Berkshire Hathaway has actually been whittling down its ...

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...

AJ Bell's Russ Mould, Danni Hewson and Dan Coatsworth point out that Berkshire Hathaway has actually been whittling down its ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial by showing improvement in liver ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

Novo Nordisk (NVO) stock gains as its weight loss drug succeeds in Phase 3 trial for the liver disease, MASH hurting Eli ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

The world’s latest AI machine is powered by the success of two products: Nvidia’s chips and Novo Nordisk’s weight-loss drugs.

Stay ahead of the market with Seeking Alpha's Wall Street Week Ahead newsletter, previewing key events like elections, Fed meeting, earnings reports.

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced promising results from the first part of its ESSENCE trial, showing that ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial ...